CORDIS
EU research results

CORDIS

English EN

Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes – Sofia ref.: 115797

Objective

Preclinical type 1 diabetes (T1D) research has made important advances in recent years, but less progress has been made in translating findings from in vitro and animal models into effective clinical interventions. INNODIA aims to achieve a breakthrough in the way in which we study T1D to enable us to move closer towards prevention and cure of T1D. To this end, INNODIA joins together the leading European experts from the fields of basic and clinical T1D research, four leading pharmaceutical companies with strong expertise in the discovery and development of diabetes medicines and the two leading public organizations involved in T1D research into one comprehensive collaborative consortium. The clinicians in INNODIA oversee T1D registries and have access to large populations of children and adults with T1D and family members at increased risk of developing the disease. The basic science researchers are experts in beta-cell pathophysiology, immunology, biomarker discovery, bioinformatics, systems biology and clinical trial design. INNODIA will accelerate understanding of T1D through coordinated studies of unique clinical samples and translation-oriented preclinical models. This should deliver novel biomarkers and interventions for testing in appropriately designed trials, to be developed in active collaboration with regulators and patients. INNODIA provides access to unique historical biorepositories and will create the Clinical Sample Network, a clinical EU infrastructure to recruit T1D subjects at diagnosis and at-risk relatives. These individuals will be deep-phenotyped and will provide biosamples, allowing the establishment of a ‘living biobank’ of subjects consented for recall. They will be characterized using standardized clinical, genetic and metabolic phenotyping procedures, including prospective, longitudinal sample collection to facilitate novel biomarker discovery. Diverse biological samples (blood, plasma, serum, urine, stools, etc.) will be collected at
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

KATHOLIEKE UNIVERSITEIT LEUVEN

Address

Oude Markt 13
3000 Leuven

Belgium

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 637 693,11

Participants (34)

Sort alphabetically

Sort by EU Contribution

Expand all

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 2 776 089

MEDIZINISCHE UNIVERSITAT GRAZ

Austria

EU Contribution

€ 250 000

UNIVERSITE LIBRE DE BRUXELLES

Belgium

EU Contribution

€ 525 926,50

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 832 000

REGION HOVEDSTADEN

Denmark

EU Contribution

€ 1 067 000

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 1 754 000

HELSINGIN YLIOPISTO

Finland

EU Contribution

€ 1 042 000

OULUN YLIOPISTO

Finland

EU Contribution

€ 365 000

TURUN YLIOPISTO

Finland

EU Contribution

€ 468 000

HANNOVERSCHE KINDERHEILANSTALT

Germany

EU Contribution

€ 631 000

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany

EU Contribution

€ 324 726

TECHNISCHE UNIVERSITAET DRESDEN

Germany

EU Contribution

€ 1 131 000

UNIVERSITAET ULM

Germany

EU Contribution

€ 360 000

UNIVERSITA DEGLI STUDI DI SIENA

Italy

EU Contribution

€ 799 528,32

UNIVERSITA DEGLI STUDI GABRIELE D'ANNUNZIO DI CHIETI-PESCARA

Italy

EU Contribution

€ 168 600

UNIVERSITA DI PISA

Italy

EU Contribution

€ 423 000

CENTRE HOSPITALIER DE LUXEMBOURG

Luxembourg

EU Contribution

€ 212 000

UNIVERSITETET I OSLO

Norway

EU Contribution

€ 3 763

SLASKI UNIWERSYTET MEDYCZNY W KATOWICACH

Poland

EU Contribution

€ 271 000

UNIVERZA V LJUBLJANI

Slovenia

EU Contribution

€ 207 000

UNIVERSITE DE LAUSANNE

Switzerland

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 388 000

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 518 926,50

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 637 087,57

UNITED KINGDOM RESEARCH AND INNOVATION

United Kingdom

EU Contribution

€ 19 423

UNIVERCELL BIOSOLUTIONS SAS

France

EU Contribution

€ 353 000

SANOFI-AVENTIS DEUTSCHLAND GMBH

Germany

NOVO NORDISK A/S

Denmark

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.

United Kingdom

Eli Lilly and Company Limited

United Kingdom

JDRF INTERNATIONAL

United States

THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST

United States

OSLO UNIVERSITETSSYKEHUS HF

Norway

EU Contribution

€ 358 237

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 106 000

Project information

Grant agreement ID: 115797

Status

Ongoing project

  • Start date

    1 November 2015

  • End date

    31 October 2022

Funded under:

H2020-EU.3.1.7.4.

  • Overall budget:

    € 36 563 723,35

  • EU contribution

    € 17 630 000

Coordinated by:

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium